Prostate-specific membrane antigen PET in prostate cancer

Courtney Lawhn-Heath; Ali Salavati; Spencer C. Behr; Steven P. Rowe; Jeremie Calais; Wolfgang P. Fendler; Mattias Eiber; Louise Emmett; Michael S. Hofman; Thomas A. Hope

doi:10.1148/RADIOL.2021202771

Prostate-specific membrane antigen PET in prostate cancer

Courtney Lawhn-Heath, Ali Salavati, Spencer C. Behr, Steven P. Rowe, Jeremie Calais, Wolfgang P. Fendler, Mattias Eiber, Louise Emmett, Michael S. Hofman, Thomas A. Hope

School of Medicine

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA PET radiopharmaceuticals, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to highlight some of the individual PSMA PET agents that have contributed to the advancement of prostate cancer imaging.

Original language	English (US)
Pages (from-to)	248-260
Number of pages	13
Journal	RADIOLOGY
Volume	299
Issue number	2
DOIs	https://doi.org/10.1148/RADIOL.2021202771
State	Published - 2021

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1148/RADIOL.2021202771

Cite this

@article{3b9b13dc0c1f411bae5bc31b32b158f7,

title = "Prostate-specific membrane antigen PET in prostate cancer",

abstract = "Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA PET radiopharmaceuticals, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to highlight some of the individual PSMA PET agents that have contributed to the advancement of prostate cancer imaging.",

author = "Courtney Lawhn-Heath and Ali Salavati and Behr, {Spencer C.} and Rowe, {Steven P.} and Jeremie Calais and Fendler, {Wolfgang P.} and Mattias Eiber and Louise Emmett and Hofman, {Michael S.} and Hope, {Thomas A.}",

note = "Publisher Copyright: {\textcopyright} RSNA, 2021.",

year = "2021",

doi = "10.1148/RADIOL.2021202771",

language = "English (US)",

volume = "299",

pages = "248--260",

journal = "RADIOLOGY",

issn = "0033-8419",

publisher = "Radiological Society of North America Inc.",

number = "2",

}

TY - JOUR

T1 - Prostate-specific membrane antigen PET in prostate cancer

AU - Lawhn-Heath, Courtney

AU - Salavati, Ali

AU - Behr, Spencer C.

AU - Rowe, Steven P.

AU - Calais, Jeremie

AU - Fendler, Wolfgang P.

AU - Eiber, Mattias

AU - Emmett, Louise

AU - Hofman, Michael S.

AU - Hope, Thomas A.

PY - 2021

Y1 - 2021

N2 - Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA PET radiopharmaceuticals, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to highlight some of the individual PSMA PET agents that have contributed to the advancement of prostate cancer imaging.

AB - Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change management plans in a substantial percentage of cases. The aims of this narrative review are to highlight the development and clinical impact of PSMA PET radiopharmaceuticals, to compare PSMA to other agents such as fluorine 18 fluciclovine and carbon 11 choline, and to highlight some of the individual PSMA PET agents that have contributed to the advancement of prostate cancer imaging.

UR - http://www.scopus.com/inward/record.url?scp=85105430002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105430002&partnerID=8YFLogxK

U2 - 10.1148/RADIOL.2021202771

DO - 10.1148/RADIOL.2021202771

M3 - Review article

C2 - 33787338

AN - SCOPUS:85105430002

SN - 0033-8419

VL - 299

SP - 248

EP - 260

JO - RADIOLOGY

JF - RADIOLOGY

IS - 2

ER -

Prostate-specific membrane antigen PET in prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this